眼表鳞状细胞瘤局部药物治疗进展  

Progress of topical pharmacotherapy for ocular surface squamous neoplasia

作　　者：李涵灵 赵志远 张慧[1] Li Hanling;Zhao Zhiyuan;Zhang Hui(Department of Ophthalmology,the Fist Affiliated Hospital of Kunming Medical University,Kunming 650000,China)

机构地区：[1]昆明医科大学第一附属医院眼科,650000

出　　处：《国际眼科纵览》2021年第5期380-386,共7页International Review of Ophthalmology

基　　金：国家自然科学基金(81560159);昆明医科大学2020年研究生创新基金项目(2020S134)。

摘　　要：眼表鳞状细胞瘤(ocular surface squamous neoplasia,OSSN)是眼科常见的眼表肿瘤,眼局部药物治疗具有非侵入性、创伤小的优点,有逐渐取代手术切除成为其首选治疗方式的趋势。目前局部药物除采用抗代谢、抗肿瘤、免疫调节作用的药物(丝裂霉素C、5-氟尿嘧啶、干扰素α2b、维甲酸等)外,一些抗肿瘤血管及病因治疗的药物(抗血管内皮生长因子类药物、西多福韦等)也被用于OSSN临床治疗研究中。Ocular surface squamous neoplasia(OSSN)is the most common ocular surface tumor.Topical pharmacotherapy,a non-invasive and less surgical trauma,has become the first way in the treatment of OSSN.At present,in addition to the chemotherapeutic drugs(such as mitomycin C,5-fluorouracil,interferonα2b,retinoic acid)with anti-metabolic,anti-tumor and immunomodulatory effects,other antiangiogenic therapy and etiological treatment(such as anti-vascular endothelial growth factor,cidofovir)have also been used in the clinical treatment of OSSN.

关 键 词：眼表鳞状细胞瘤 局部药物治疗 非手术治疗 

分 类 号：R739.7[医药卫生—肿瘤]